Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion
Resent due to technical problems news distributor. Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals with Phenylketonuria. Initially, the at-home PHE test will be available as a research-use-only (CE-RUO) product, designed to supplement existing testing routines until it receives full regulatory approval. The company plans to begin the process of registering the test as an in-vitro diagnostic (IVD) later this year, starting in the UK and expanding to the EU and other markets.An at-home PHE test will